Deals

Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review
CancerEli Lilly

Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review

Foghorn Therapeutics Inc. (NASDAQ: FHTX) announced that, following a review of clinical data from the Phase 1 dose‑escalation trial of FHD‑909 (LY4050784), both Foghorn and Eli Lilly and Company (NYSE:…

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

GE HealthCare to Acquire SOFIE Biosciences for $945M – Bolstering PET Radiopharmaceutical Manufacturing and Securing Phase III FAPI‑74 Asset

GE HealthCare to Acquire SOFIE Biosciences for $945M – Bolstering PET Radiopharmaceutical Manufacturing and Securing Phase III FAPI‑74 Asset

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
ADC / XDCCancer

Full-Life Technologies Strikes USD 571.5 Million Licensing Deal with SK Biopharmaceuticals for Radiopharmaceutical Asset

CancerGenomics / NGS

MGI Tech Partners with Predica Diagnostics to Advance RNA Sequencing in Cancer Detection

CRO / CMO / CDMOLionco Pharmaceutical

Lionco Pharmaceutical Partners with Laboratoire Bailly-Creat to Expand Overseas

CAR-TCell-therapy

Nona Biosciences Partners with Alaya.bio to Revolutionize CAR-T Therapy Development

Show More